Merck & Company, Inc. Press Releases

MRK 
$49.38
*  
0.79
1.63%
Get MRK Alerts
*Delayed - data as of Feb. 5, 2016  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    MRK Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG and Merck's Checkpoint Inhibitor Keytruda in Patients with Non-Small Cell Lung Cancer
12/10/2015 9:00:00 AM - Business Wire
▼-6.51 % Price Change since this news event. The Volume Ratio is 1.23.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA® (pembrolizumab) Data
12/8/2015 8:00:00 AM - Business Wire
▼-8.04 % Price Change since this news event. The Volume Ratio is 0.74.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS™ (Infliximab), a Biosimilar of Remicade, in Korea
12/7/2015 8:00:00 AM - Business Wire
▼-9.46 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Responses Observed in Three-Quarters of Heavily Pre-Treated Multiple Myeloma Patients Receiving KEYTRUDA® (pembrolizumab) Combined With Lenalidomide and Dexamethasone
12/7/2015 7:00:00 AM - Business Wire
▼-7.84 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Merck Announces Increased Quarterly Dividend
11/24/2015 12:35:00 PM - Business Wire
















Merck Provides Update on REVEAL Outcomes Study
11/13/2015 8:00:00 AM - Business Wire




Merck Animal Health to Acquire Harrisvaccines
11/12/2015 5:00:00 PM - Business Wire





Learn more by visiting our FAQ page